Rationale and design of the SMART Heart study - A prediction model for left ventricular hypertrophy in hypertension

被引:10
作者
Meijs, M. F. L. [1 ,2 ]
Bots, M. L. [3 ]
A-Vonken, E-J. [2 ]
Cramer, M-J. M. [1 ]
Melman, P. G. [1 ]
Velthuis, B. K. [2 ]
van der Graaf, Y. [3 ]
Mali, W. P. Th. M. [2 ]
Doevendans, P. A. [1 ]
机构
[1] Univ Med Ctr Utrecht, Dept Cardiol, NL-3508 GA Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Dept Radiol, NL-3508 GA Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands
来源
NETHERLANDS HEART JOURNAL | 2007年 / 15卷 / 09期
关键词
hypertrophy; MRI; single nucleotide polymorphism (SNP); risk prediction; delayed enhancement; CARDIOVASCULAR MAGNETIC-RESONANCE; STRAIN-RATE; FAILURE; DYSFUNCTION; ECHOCARDIOGRAPHY; MASS; REGRESSION; GEOMETRY;
D O I
10.1007/BF03086003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Left ventricular hypertrophy (LVH) is an independent risk factor for the development of heart failure, coronary heart disease and stroke. LVH develops in response to haemodynamic overload, e.g. hypertension. LVH was originally thought to start as an adaptive and beneficial response required to normalise wall stress. However, this concept has been challenged by recent animal experiments suggesting that any degree of LVH is detrimental for the preservation of cardiac function and survival. If confirmed in humans, these findings imply that an increase in LV mass should be prevented, e.g. by lifestyle or pharmacological interventions. To facilitate and optimise interventions, the SMART Heart study was recently set up to develop a prediction model, also involving single nucleotide polymorphism data, for the identification of subjects at high risk of developing LVH in hypertension. For this purpose 1000 subjects with chronic hypertension will undergo cardiac MR imaging. In addition, this study allows the extrapolation of animal experimental genetic research into the human situation.
引用
收藏
页码:295 / 298
页数:4
相关论文
共 25 条
[1]   Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study [J].
Arnold, JMO ;
Yusuf, S ;
Young, J ;
Mathew, J ;
Johnstone, D ;
Avezum, A ;
Lonn, E ;
Pogue, J ;
Bosch, J .
CIRCULATION, 2003, 107 (09) :1284-1290
[2]   Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension [J].
Brown, DW ;
Giles, WH ;
Croft, JB .
AMERICAN HEART JOURNAL, 2000, 140 (06) :848-856
[3]   REVERSAL OF LEFT-VENTRICULAR HYPERTROPHY IN HYPERTENSIVE PATIENTS - A METAANALYSIS OF 109 TREATMENT STUDIES [J].
DAHLOF, B ;
PENNERT, K ;
HANSSON, L .
AMERICAN JOURNAL OF HYPERTENSION, 1992, 5 (02) :95-110
[4]   Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol -: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial [J].
Devereux, RB ;
Dahlöf, B ;
Gerdts, E ;
Boman, K ;
Nieminen, MS ;
Papademetriou, V ;
Rokkedal, J ;
Harris, KE ;
Edelman, JM ;
Wachtell, K .
CIRCULATION, 2004, 110 (11) :1456-1462
[5]   Left ventricular systolic dysfunction in a biracial sample of hypertensive adults - The HyperGEN study [J].
Devereux, RB ;
Bella, JN ;
Palmieri, V ;
Oberman, A ;
Kitzman, DW ;
Hopkins, PN ;
Rao, DC ;
Morgan, D ;
Paranicas, M ;
Fishman, D ;
Arnett, DK .
HYPERTENSION, 2001, 38 (03) :417-423
[6]   Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years [J].
Drazner, MH ;
Rame, JE ;
Marino, EK ;
Gottdiener, JS ;
Kitzman, DW ;
Gardin, JM ;
Manolio, TA ;
Dries, DL ;
Siscovick, DS .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (12) :2207-2215
[7]   Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress [J].
Esposito, G ;
Rapacciuolo, A ;
Prasad, SVN ;
Takaoka, H ;
Thomas, SA ;
Koch, WJ ;
Rockman, HA .
CIRCULATION, 2002, 105 (01) :85-92
[8]   Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy [J].
Grothues, F ;
Smith, GC ;
Moon, JCC ;
Bellenger, NG ;
Collins, P ;
Klein, HU ;
Pennell, DJ .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (01) :29-34
[9]   Technology Insight: assessment of myocardial viability by delayed-enhancement magnetic resonance imaging [J].
Judd, RM ;
Wagner, A ;
Rehwald, WG ;
Albert, T ;
Kim, RJ .
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2005, 2 (03) :150-158
[10]  
Kannel W B, 1987, J Cardiovasc Pharmacol, V10 Suppl 6, pS135, DOI 10.1097/00005344-198700106-00018